The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label phase 1 trial of the safety and efficacy of daily subcutaneous SPL-108 injections when used in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer.
 
Eugenia Girda
No Relationships to Disclose
 
Alexandre Buckley de Meritens
No Relationships to Disclose
 
Malcolm Finlayson
Employment - Splash Pharmaceuticals
Leadership - Splash Pharmaceuticals
Stock and Other Ownership Interests - Hologic (I); Splash Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Splash Pharmaceuticals
 
Aliza Leiser
No Relationships to Disclose
 
David Nelson
Employment - Provista Diagnostics; Splash Pharmaceuticals
Leadership - Provista Diagnostics; Splash Pharmaceuticals
Stock and Other Ownership Interests - Splash Pharmaceuticals
Consulting or Advisory Role - Provista Diagnostics; Splash Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Splash Pharmaceuticals
Travel, Accommodations, Expenses - Provista Diagnostics; Splash Pharmaceuticals
 
Michael H. Silverman
Stock and Other Ownership Interests - Can-Fite BioPharma; Dipexium
Consulting or Advisory Role - Can-Fite BioPharma; Cascade Prodrug; Dipexium; Kaleido Biosciences; Neovia Oncology; Phosplatin Therapeutics; Samus Therapeutics; Splash Pharmaceuticals; Taiwan Liposome; Takeda; Zenith Epigenetics
 
Ruth Stephenson
No Relationships to Disclose
 
Lorna Rodriguez-Rodriguez
No Relationships to Disclose